Welcome to our dedicated page for AbbVie SEC filings (Ticker: ABBV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AbbVie Inc. filings document formal disclosures for a global pharmaceutical issuer with common stock and multiple senior note series registered on the New York Stock Exchange. Recent Form 8-K reports cover quarterly and annual results, preliminary earnings impacts from acquired IPR&D and milestone expenses, material-event disclosures, material agreements and capital-structure updates.
The company’s filing record also includes debt-financing disclosures for completed senior note offerings and definitive proxy materials covering board matters, executive compensation, equity awards and shareholder voting items. These documents provide regulatory detail on AbbVie’s operating results, listed securities, governance framework and financing activity.
AbbVie Inc. executive vice president and chief operations officer Azita Saleki-Gerhardt reported equity compensation grants. She received an employee stock option for 20,312 shares at a grant price of $0.00, vesting in three annual installments of 6,771, 6,771 and 6,770 shares on February 18, 2027, February 18, 2028, and February 18, 2029.
She also acquired multiple blocks of AbbVie common stock through performance-based share and restricted stock unit awards, with grants from February 16, 2023, February 15, 2024, and February 13, 2025 tied to earnings per share, relative total shareholder return, and relative return on equity. These performance-vesting restrictions were certified as attained on February 18, 2026, and the shares will be issued on February 28, 2026. Additional indirect holdings include shares in an AbbVie savings program and shares held by her spouse, for which she disclaims beneficial ownership.
AbbVie Inc. executive Demetris D. Crum, EVP and Chief HR Officer, reported equity compensation awards rather than open-market trades. On February 18, 2026, Crum was granted options for 13,406 shares of AbbVie common stock under the AbbVie Amended and Restated 2013 Incentive Stock Program. These options become exercisable in three annual installments of 4,469 shares on February 18, 2027, 4,469 shares on February 18, 2028, and 4,468 shares on February 18, 2029.
Crum also acquired 1,216 shares and 1,244 shares of AbbVie common stock tied to performance-vesting restricted stock unit awards originally granted on February 15, 2024 and February 13, 2025, respectively. These awards vest based on a relative return on equity measure, with performance certified by AbbVie’s Compensation Committee, and the shares are scheduled to be issued on February 28, 2026.
AbbVie executive Nicholas Donoghoe reported multiple equity awards tied to performance goals. On February 18, 2026, he acquired an option to buy 20,312 AbbVie shares, vesting in three equal annual installments starting on February 18, 2027.
He also received performance-based stock awards of 13,031, 4,632, 5,172 and 6,222 AbbVie shares. These stock units vested after AbbVie’s Compensation Committee certified achievements in earnings per share, relative total shareholder return and relative return on equity, with shares scheduled to be issued on February 28, 2026.
AbbVie Inc. executive vice president and chief financial officer Scott T. Reents reported equity awards that increase his direct stake in the company. On February 18, 2026, he acquired an option for 21,937 shares of AbbVie common stock at an exercise price set by the plan, with the option vesting in annual increments of 7,313 shares on February 18, 2027 and 7,312 shares on February 18, 2028 and February 18, 2029. He was also credited with multiple performance-based share and restricted stock unit awards totaling 48,838 shares of common stock, granted in 2023, 2024, and 2025. These awards vested after AbbVie’s Compensation Committee certified the achievement of performance goals tied to earnings per share, relative total shareholder return, and relative return on equity, and the underlying shares are scheduled to be issued to him on February 28, 2026.
AbbVie Inc. reported that Chief Executive Officer Michael Robert A. acquired new equity incentives in the form of stock options and performance-based stock awards. On February 18, 2026, he received an option grant for 81,251 shares at an exercise price listed as $0.00 per share, which reflects an incentive award structure rather than a market purchase.
He was also credited with several performance-vesting share awards of AbbVie common stock tied to prior grants. These include 33,833 shares from a performance share award granted on February 16, 2023, and additional performance-vesting restricted stock unit awards of 12,030, 14,452 and 22,124 shares from grants dated February 16, 2023, February 15, 2024 and February 13, 2025. The performance conditions were based on earnings per share, relative total shareholder return and relative return on equity, and were certified by the Compensation Committee, releasing the vesting restrictions.
The shares from these performance-based awards are scheduled to be issued to the CEO on February 28, 2026. The stock option becomes exercisable in three annual installments of 27,084 shares on February 18, 2027, 27,084 shares on February 18, 2028, and 27,083 shares on February 18, 2029.
AbbVie Inc. is a global, research-driven biopharmaceutical company operating as a single business segment with leadership positions in immunology, neuroscience, oncology, aesthetics, eye care and other specialty therapeutics. Its portfolio includes major brands such as Skyrizi, Rinvoq, Humira, Vraylar, Imbruvica, Venclexta, Botox Cosmetic and Juvederm.
Skyrizi and Rinvoq are now central growth drivers, together accounting for approximately 42% of AbbVie’s total net revenues in 2025. The company emphasizes proprietary biologics and complex therapies, supported by substantial research and development, extensive global manufacturing, and broad marketing and distribution capabilities across more than 70 countries.
AbbVie highlights significant risks, including loss of exclusivity and biosimilar or generic competition, particularly for key biologics; pricing and reimbursement pressure globally, including U.S. Medicare reforms under the Inflation Reduction Act that will impose government-set prices on products such as Imbruvica, Vraylar, Linzess and Botox; and potential challenges to its extensive patent portfolio. The company also notes regulatory, environmental and supply-chain obligations and relies on collaborations, third‑party manufacturers and raw-material suppliers to support operations.
AbbVie Inc. filed a current report stating that it issued a press release with its financial results for the fourth quarter and full year ended December 31, 2025. The company released these results on February 4, 2026, and attached the full press release as Exhibit 99.1.
The filing is presented under the Results of Operations and Financial Condition section, indicating the update relates to AbbVie’s operating performance and overall financial health for 2025. Detailed figures and metrics are contained in the referenced press release rather than in this summary document.
AbbVie Inc. updated its earnings outlook to reflect a large research and development charge in the fourth quarter of 2025. The company expects acquired in-process R&D and milestones expense of $1.3 billion on a pre-tax basis, which is estimated to reduce both GAAP diluted EPS and adjusted non-GAAP diluted EPS by $0.71 per share for the quarter.
Including this fourth quarter expense, AbbVie now expects its full-year 2025 adjusted diluted EPS to be in the range of $9.90–$9.94. For the fourth quarter of 2025, adjusted diluted EPS is guided to a range of $2.61–$2.65. The company notes that results for the quarter ended December 31, 2025 are preliminary and subject to completion of its financial closing procedures.
AbbVie Inc. director Robert J. Alpern reported a routine compensation-related transaction. On 12/31/2025, he acquired 34 stock equivalent units tied to AbbVie common stock at $228.49 per unit, bringing his total holdings of these derivative securities to 10,257 stock equivalent units.
According to the disclosure, these units represent director fees credited to stock equivalent unit accounts under grantor trusts established at Abbott Laboratories and AbbVie. The units are paid out in cash, generally at age 65 or upon retirement from each company’s board, and earn the same return as if the fees were invested in AbbVie stock. The reported balance also reflects units acquired through a dividend reinvestment feature.
AbbVie Inc. director equity filing: A Form 4 reports that a director of AbbVie received 68 stock equivalent units on 12/31/2025 at a reference value of $228.49 per unit. These units are credited as director fees into a stock equivalent unit account in a grantor trust and are generally paid in cash at about age 65 or upon retirement from the board. After this transaction, the director beneficially owns 707 stock equivalent units, which are designed to earn the same return as if the fees were invested directly in AbbVie common stock, including through a dividend reinvestment feature.